Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Endometrial ablation

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    14 result(s) found for: Endometrial ablation. Displaying page 1 of 1.
    EudraCT Number: 2009-016858-41 Sponsor Protocol Number: E7080-G000-204 Start Date*: 2010-10-05
    Sponsor Name:Eisai Ltd.
    Full Title: An Open-Label, Single-Arm, Multicenter Phase 2 Study of E7080 in Subjects with Advanced Endometrial Cancer and Disease Progression Following First-Line Chemotherapy
    Medical condition: Unresectable endometrial cancer and disease progression following platinum-based, first-line chemotherapy
    Disease: Version SOC Term Classification Code Term Level
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10014740 Endometrial cancer stage III PT
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10014736 Endometrial cancer recurrent PT
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10014734 Endometrial cancer metastatic PT
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10014741 Endometrial cancer stage IV PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: HU (Completed) BG (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2009-011775-78 Sponsor Protocol Number: 08GINE1 Start Date*: 2009-01-20
    Sponsor Name:UNIVERSITA` CAMPUS BIOMEDICO
    Full Title: Evaluation of efficacy of antibiotic prophylaxis in patients undergoing operative hysteroscopy
    Medical condition: Patients needing operative hysteroscopy
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2019-003600-12 Sponsor Protocol Number: MORAb-202-G000-201 Start Date*: 2022-07-25
    Sponsor Name:Eisai Limited
    Full Title: A Multicenter, Open-Label Phase 1/2 Trial Evaluating the Safety, Tolerability, and Efficacy of MORAb-202, a folate receptor alpha (FRĪ±)-targeting antibody-drug conjugate (ADC) in Subjects With Sele...
    Medical condition: Solid tumors expressing folate receptor alpha in 4 tumor types: platinum resistant ovarian cancer, triple-negative breast cancer (TNBC), endometrial cancer (EC), and non-small cell lung cancer aden...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10033128 Ovarian cancer PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10075566 Triple negative breast cancer PT
    21.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10014733 Endometrial cancer PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned) ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-000300-26 Sponsor Protocol Number: E7080-A001-111 Start Date*: 2017-10-20
    Sponsor Name:Eisai Ltd.
    Full Title: A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors
    Medical condition: Non-small cell lung cancer, predominantly clear cell renal cell carcinoma, endometrial carcinoma, urothelial carcinoma, squamous cell carcinoma of the head and neck, or melanoma (excluding uveal me...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10014733 Endometrial cancer PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060121 Squamous cell carcinoma of head and neck PT
    20.0 100000017553 10064467 Urothelial carcinoma LLT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10067946 Renal cell carcinoma PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10061873 Non-small cell lung cancer PT
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025650 Malignant melanoma PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) NO (Completed)
    Trial results: View results
    EudraCT Number: 2006-001629-24 Sponsor Protocol Number: VAG-1748 Start Date*: 2006-10-26
    Sponsor Name:Novo Nordisk A/S
    Full Title: A 12 month, open-label, multi-center trial to investigate the endometrial safety of Vagifem Low Dose (10ug 17beta-estradiol vaginal tablet) in postmenopausal women with atrophic vaginitis symptoms....
    Medical condition: atrophic vaginitis
    Disease: Version SOC Term Classification Code Term Level
    8.1 10003690 Atrophic vaginitis LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: FR (Completed) SE (Completed) DK (Completed) FI (Completed) CZ (Completed) HU (Completed)
    Trial results: View results
    EudraCT Number: 2013-005494-53 Sponsor Protocol Number: Start Date*: 2014-10-16
    Sponsor Name:Norfolk and Norwich University Hospitals NHS Foundation Trust
    Full Title: A Study of the Histopathological Changes within Ectopic Endometrial Tissue, in Subjects with Known Pelvic Endometriosis Following Treatment with Ulipristal Acetate, a Selective Progesterone Recepto...
    Medical condition: Endometriosis
    Disease: Version SOC Term Classification Code Term Level
    17.0 10042613 - Surgical and medical procedures 10057902 Endometriosis ablation PT
    17.0 10038604 - Reproductive system and breast disorders 10014785 Endometriosis of pelvic peritoneum LLT
    17.0 10038604 - Reproductive system and breast disorders 10014788 Endometriosis related pain LLT
    17.0 10042613 - Surgical and medical procedures 10014779 Endometriosis in pelvis, excision LLT
    17.0 10038604 - Reproductive system and breast disorders 10014778 Endometriosis PT
    Population Age: Adults Gender: Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2014-003408-65 Sponsor Protocol Number: Start Date*: 2016-08-26
    Sponsor Name:University of Edinburgh [...]
    1. University of Edinburgh
    2. NHS Lothian
    Full Title: Ulipristal acetate versus conventional management of heavy menstrual bleeding (HMB; including uterine fibroids): a randomised controlled trial and exploration of mechanism of action (UCON trial)
    Medical condition: Heavy menstrual bleeding
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004864 10046784 Uterine fibroids LLT
    18.0 10038604 - Reproductive system and breast disorders 10027313 Menorrhagia PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2017-001588-19 Sponsor Protocol Number: MVT-601-3101 Start Date*: 2017-11-01
    Sponsor Name:Myovant Sciences GmbH
    Full Title: SPIRIT 1: An International Phase 3 Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study to Evaluate Relugolix Administered with and without Low-Dose Estradiol and Norethindrone Ac...
    Medical condition: Endometriosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10038604 - Reproductive system and breast disorders 10014778 Endometriosis PT
    Population Age: Adults Gender: Female
    Trial protocol: CZ (Completed) ES (Completed) HU (Completed) BE (Completed) PL (Completed) BG (Completed) PT (Completed) FI (Completed)
    Trial results: View results
    EudraCT Number: 2017-001632-19 Sponsor Protocol Number: MVT-601-3102 Start Date*: 2017-12-01
    Sponsor Name:Myovant Sciences GmbH
    Full Title: SPIRIT 2: An International Phase 3 Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study to Evaluate Relugolix Administered with and without Low-Dose Estradiol and Norethindrone Ac...
    Medical condition: Endometriosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10038604 - Reproductive system and breast disorders 10014778 Endometriosis PT
    Population Age: Adults Gender: Female
    Trial protocol: SE (Completed) CZ (Completed) PL (Completed) GB (Completed) IT (Completed) RO (Completed)
    Trial results: View results
    EudraCT Number: 2016-005113-50 Sponsor Protocol Number: MVT-601-3002 Start Date*: 2017-05-22
    Sponsor Name:Myovant Sciences GmbH
    Full Title: LIBERTY 2: An International Phase 3 Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study to Evaluate Relugolix Co Administered with and without Low-Dose Estradiol and Norethindron...
    Medical condition: heavy menstrual bleeding associated with uterine fibroids
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004872 10027331 Menstrual flow altered LLT
    20.0 100000004864 10046783 Uterine fibroid LLT
    Population Age: Adults Gender: Female
    Trial protocol: HU (Completed) CZ (Completed) BE (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2016-003727-27 Sponsor Protocol Number: MVT-601-3001 Start Date*: 2017-06-12
    Sponsor Name:Myovant Sciences GmbH c/o Vischer AG
    Full Title: LIBERTY 1: An International Phase 3 Randomized, Double-Blind, Placebo-Controlled Efficacy and Safety Study to Evaluate Relugolix Co Administered with and without Low-Dose Estradiol and Norethindron...
    Medical condition: heavy menstrual bleeding associated with uterine fibroids
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004872 10027331 Menstrual flow altered LLT
    20.0 100000004864 10046783 Uterine fibroid LLT
    Population Age: Adults Gender: Female
    Trial protocol: GB (Completed) DE (Completed) PL (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2015-001553-32 Sponsor Protocol Number: MR/M024954/1 Start Date*: 2015-10-09
    Sponsor Name:Imperial College, Joint Research Compliance Office
    Full Title: Neurokinin 3 Receptor Antagonism as a Novel Treatment for Menopausal Hot Flushes
    Medical condition: menopausal hot flushes
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004872 10027311 Menopause flushing LLT
    Population Age: Adults Gender: Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2008-001804-22 Sponsor Protocol Number: PGL07-021 Start Date*: 2008-10-16
    Sponsor Name:PregLem S.A.
    Full Title: A Phase III, randomized, parallel group, double-blind, placebo-controlled, multi-center study to assess the efficacy and safety of PGL4001 (ulipristal) versus placebo for pre-operative treatment of...
    Medical condition: Uterine myoma are benign, monoclonal, hormone sensitive, smooth muscle tumors of the uterus. It is the most common tumor of the female reproductive tract in pre-menopausal women and mostly asympto...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10046801 Uterine myoma LLT
    Population Age: Adults Gender: Female
    Trial protocol: CZ (Completed) HU (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-001805-40 Sponsor Protocol Number: PGL07-022 Start Date*: 2008-07-28
    Sponsor Name:PregLem S.A.
    Full Title: A Phase III, randomised, parallel group, double-blind, double-dummy, active comparator -controlled, multi-center study to assess the efficacy and safety of PGL4001 (ulipristal) versus GnRH-agonist ...
    Medical condition: Uterine myomas are benign, monoclonal, hormone sensitive, smooth muscle tumors of the uterus. It is the most common tumor of the female reproductive tract in pre-menopausal women and mostly asympt...
    Disease: Version SOC Term Classification Code Term Level
    9.1 10046801 Uterine myoma LLT
    Population Age: Adults Gender: Female
    Trial protocol: BE (Completed) ES (Completed) AT (Completed) FR (Completed) IT (Completed) PL (Completed) DE (Completed) NL (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat May 10 19:46:56 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA